Abbott Laboratories (ABT) : Hendershot Investments reduced its stake in Abbott Laboratories by 2.38% during the most recent quarter end. The investment management company now holds a total of 60,788 shares of Abbott Laboratories which is valued at $2,654,612 after selling 1,485 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.Abbott Laboratories makes up approximately 1.31% of Hendershot Investments’s portfolio.
Other Hedge Funds, Including , Armstrong Henry H Associates Inc reduced its stake in ABT by selling 300 shares or 0.92% in the most recent quarter. The Hedge Fund company now holds 32,421 shares of ABT which is valued at $1,415,825. Abbott Laboratories makes up approx 0.27% of Armstrong Henry H Associates Inc’s portfolio.Sigma Planning Corp reduced its stake in ABT by selling 34,821 shares or 54.62% in the most recent quarter. The Hedge Fund company now holds 28,926 shares of ABT which is valued at $1,248,735. Abbott Laboratories makes up approx 0.16% of Sigma Planning Corp’s portfolio.Cibc World Markets boosted its stake in ABT in the latest quarter, The investment management firm added 26,144 additional shares and now holds a total of 77,020 shares of Abbott Laboratories which is valued at $3,324,953. Abbott Laboratories makes up approx 0.01% of Cibc World Markets’s portfolio.Grassi Investment Management boosted its stake in ABT in the latest quarter, The investment management firm added 97,700 additional shares and now holds a total of 112,125 shares of Abbott Laboratories which is valued at $4,705,886. Abbott Laboratories makes up approx 0.87% of Grassi Investment Management’s portfolio.First American Trust Fsb reduced its stake in ABT by selling 2,888 shares or 5.55% in the most recent quarter. The Hedge Fund company now holds 49,185 shares of ABT which is valued at $2,060,360. Abbott Laboratories makes up approx 0.72% of First American Trust Fsb’s portfolio.
Abbott Laboratories opened for trading at $44.38 and hit $45.12 on the upside on Friday, eventually ending the session at $44.75, with a gain of 0.67% or 0.3 points. The heightened volatility saw the trading volume jump to 1,34,23,155 shares. Company has a market cap of $65,745 M.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.